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Abstract Adenosine and mitogen-activated protein kinases
(MAPKs) have been separately implicated in cardiac ischaemic
preconditioning. We investigated the activation of MAPK
subfamilies by adenosine in perfused rat hearts. p38-MAPK
was rapidly phosphorylated and activated (10-fold activation,
maximal at 5 min) by 10 mM adenosine, as was the p38-MAPK
substrate, MAPKAPK2 (4.5-fold). SAPKs/JNKs were activated
(5-fold) and ERKs were phosphorylated (both maximal at 5 min).
The concentration dependences of activation of p38-MAPK and
ERKs were biphasic with a ‘high affinity’ component (maximal
at 10^100 WM adenosine) and a ‘low affinity’ component that had
not saturated at 10 mM. SAPKs/JNKs were activated only by 10
mM adenosine. These results are consistent with MAPK
involvement in adenosine-mediated ischaemic preconditioning.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Adenosine (Ado) is formed in the heart by the hydrolysis of
adenine nucleotides, a process that occurs extensively in is-
chaemia and reperfusion [1]. Ado may be an endogenous me-
diator of ischaemic preconditioning, where brief periods of
sublethal ischaemia increase the heart’s resistance to subse-
quent periods of more severe ischaemia [1^4]. Ado exerts its
preconditioning e¡ects, at least in part, through the activation
of Gi protein-coupled Ado receptor A1 and A3 subtypes
[1,3,4]. The signalling mechanisms responsible for ischaemic
preconditioning are unclear and are the subject of intense
investigation. Several groups have demonstrated that mito-
gen-activated protein kinase (MAPK) subfamilies are acti-
vated by ischaemic preconditioning protocols [5^7]. p38-
MAPKs are activated during ischaemia and this is maintained
during subsequent reperfusion. Stress-activated protein kin-
ases (SAPKs), which are also known as c-Jun N-terminal
kinases (JNKs), are activated during reperfusion following
ischaemia. It is not clear whether a third group of MAPKs,
the extracellularly responsive kinases (ERKs), is activated by
ischaemic preconditioning. Recently, p38-MAPK has been di-
rectly implicated in ischaemic preconditioning [8] and here we
have examined the regulation of all three MAPK subfamilies
in the perfused heart by Ado.
2. Materials and methods
2.1. Heart perfusions
Adult male (275^325 g) Sprague-Dawley rat hearts were perfused
retrogradely as described previously [9]. After a 15 min equilibration
period, hearts were perfused with Ado for a further 2^30 min or with
1 WM phorbol 12-myristate 13-acetate (PMA) for 5 min. Hearts were
also subjected to ischaemia/reperfusion as previously described [9].
Control hearts were perfused for up to 30 min following equilibration.
Hearts were ‘freeze-clamped’ whilst still perfusing and pulverised
under liquid N2. Heart extracts were prepared using the extraction
bu¡ers described previously [9] and clari¢ed by centrifugation
(10 000Ug, 10 min). Protein concentrations were determined using
the biuret method [10].
2.2. Protein kinase assays
For in gel kinase assays, proteins (60 Wg) were separated on 10% (w/
v) SDS-polyacrylamide gels with a 6% (w/v) stacking gel. The 10%
gels were formed in the presence of 0.5 mg/ml recombinant MAPK-
activated protein kinase 2 (MAPKAPK2) catalytic domain (residues
46^400) for assay of p38-MAPKs or 0.5 mg/ml recombinant c-Jun
transactivation domain (residues 1^135) for assay of SAPKs/JNKs.
In gel assays were performed as previously described [6,11] except
that, during the phosphorylation, gels were incubated for 1 h with
25 WCi/gel [Q-32P]ATP (NEN) in 10 ml 40 mM HEPES pH 8.0, 0.5
mM EGTA, 10 mM MgCl2, 15 mM ATP, 0.1 mM cyclic AMP-de-
pendent protein kinase inhibitory peptide. Gels were dried onto 3MM
Whatman paper and autoradiographed, with quanti¢cation by laser
scanning densitometry.
Western blots for phospho-p38-MAPK and phospho-ERK1/2 were
performed with antibodies (New England Biolabs) against the dually
phosphorylated (activated) species according to the manufacturer’s
instructions. The bands were detected using the ECL method (Amer-
sham) with quanti¢cation by laser scanning densitometry.
MAPKAPK2 was partially puri¢ed by Mono S fast protein liquid
chromatography (FPLC) and assayed as previously described [9].
3. Results
Ado (10 mM) stimulated the phosphorylation of p38-
MAPK as assessed by immunoblotting (Fig. 1A). This was
maximal at 5 min and declined thereafter, although it re-
mained elevated for at least 30 min. The degree of phosphor-
ylation was comparable to that induced by 20 min ischaemia/
10 min reperfusion. Maximal activation (10-fold relative to
controls, as assessed by in gel assays) of p38-MAPKs was
observed at 5 min, and activity remained elevated for at least
30 min (Fig. 1B). This activation was comparable to that
induced by ischaemia/reperfusion. We also examined activa-
tion of MAPKAPK2, which is phosphorylated and activated
by p38-MAPK [12]. Ado (10 mM) stimulated a single peak of
activity which eluted at approximately 0.18 M NaCl on Mono
S FPLC (results not shown). MAPKAPK2 was activated ap-
proximately 4.5-fold relative to controls at 5 min and re-
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mained elevated at 30 min (approximately 3-fold) (Fig. 1C).
As with p38-MAPK, MAPKAPK2 activation by Ado was
comparable to that in hearts subjected to ischaemia/reperfu-
sion. The concentration-dependence of p38-MAPK phosphor-
ylation and activation was biphasic (Fig. 2A^C). Phosphory-
lation (Fig. 2A) and activation (Fig. 2B) was detectable at 0.3
WM and increased over a narrow concentration range (0.3^3.0
WM, Fig. 2C). Following a plateau (10 WM^0.3 mM), there
was a second marked increase that had not saturated at 10
mM Ado.
Ado (10 mM) also rapidly activated both p46 and p54
SAPKs/JNKs (maximal 6-fold activation relative to controls
at 5 min) with activities remaining elevated for 30 min (Fig.
3A). As with p38-MAPK, activation of the SAPKs/JNKs by
Ado was comparable to that by ischaemia/reperfusion. Unlike
p38-MAPK, the SAPKs/JNKs were only strongly activated by
high concentrations (10 mM) of Ado (Fig. 3B).
Phosphorylation of ERK1 (44 kDa) and ERK2 (42 kDa)
induced by 10 mM Ado was maximal at 5 min and remained
elevated for 30 min (Fig. 4A). PMA is the most powerful
activator of cardiac ERKs so far identi¢ed [13], and the re-
sponse of ERKs to 10 mM Ado was about 40% of that seen in
hearts perfused with 1 WM PMA in this example (Fig. 4A).
The concentration dependence of ERK phosphorylation was
also examined (Fig. 4B) and displayed a biphasic pattern (Fig.
4C) similar to that seen for p38-MAPK (Fig. 2C).
4. Discussion
We and others have shown that p38-MAPK and its sub-
strate MAPKAPK2 are strongly activated by myocardial is-
chaemia and their activation is maintained on reperfusion
[6,7]. SAPKs/JNKs are strongly activated during the reperfu-
sion phase [5^7]. The activation of these MAPKs may be
partly mediated by the release of reactive oxygen species.
Exogenous H2O2 activates MAPKs in perfused heart [9],
and the e¡ects of ischaemia/reperfusion on MAPKs can be
reduced by antioxidants [9]. Analogous e¡ects have been ob-
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Fig. 1. Activation of p38-MAPK and MAPKAPK2 in hearts per-
fused with Ado. Hearts were perfused with 10 mM Ado for the
times indicated, perfused under control conditions (C), or rendered
ischaemic (20 min) and then reperfused (20 min) (I/R). A: p38-
MAPK phosphorylation in extracts was determined using an anti-
body against phospho-p38-MAPK. B: The time course of p38-
MAPK activation in the extracts was examined by in gel assays
with recombinant MAPKAPK2(46^400) as substrate. C: MAPK-
APK2 activity in hearts perfused with 10 mM Ado, as determined
by Mono S FPLC. The experiment was repeated with similar re-
sults.
Fig. 2. Concentration-dependent phosphorylation and activation of
p38-MAPK in hearts perfused with Ado. Hearts were perfused for
5 min with Ado. To assist with comparison, the separate gels con-
tained samples at overlapping Ado concentrations. I/R, hearts ren-
dered ischaemic for 20 min and reperfused for 10 min. A: Concen-
tration-dependent phosphorylation of p38-MAPK by Ado as
determined by immunoblotting. B: Concentration-dependent activa-
tion of p38-MAPK by Ado as determined by in gel assays.
C: Quanti¢cation of p38-MAPK phosphorylation (F, solid line) and
activation (b, dashed line). Results were expressed relative to the
signal in ischaemic/reperfused hearts. The experiment was repeated
with similar results.
Fig. 3. Activation of SAPKs/JNKs in hearts perfused with Ado. A:
Hearts were perfused with 10 mM Ado for the times indicated and
SAPK/JNK activity was determined by in gel kinase assays with c-
Jun(1^135) as substrate. B: Concentration-dependent activation of
SAPKs/JNKs by Ado as determined by in gel assays. Hearts were
perfused for 5 min with Ado. To assist with comparison, the sepa-
rate gels contained samples at overlapping Ado concentrations. I/R,
hearts rendered ischaemic for 20 min and reperfused for 10 min.
The experiment was repeated with similar results.
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served in cardiac myocytes [14^17]. Since exogenous Ado is a
powerful preconditioning agent [1], we tested its e¡ects on the
activation of three MAPK subfamilies.
MAPKs are activated by dual phosphorylation of a Thr-
Xaa-Tyr motif by dual-speci¢city MAPK kinases. Here, we
have examined phosphorylation (p38-MAPK and ERKs) or
activation (p38-MAPK and SAPKs/JNKs), the two processes
being equivalent. For all MAPKs, Ado (10 mM) induced
rapid phosphorylation and/or activation that was maximal
within 5 min (Fig. 1AFig. 3AFig. 4A). For p38-MAPK and
SAPKs/JNKs, the activation was comparable to that induced
by ischaemia/reperfusion. For ERKs, the response was ap-
proximately 40% of that induced by PMA. These treatments
powerfully activate the respective MAPKs [6,13]. MAPK-
APK2 was also powerfully activated by 10 mM Ado (Fig.
1C). p38-MAPKs (Fig. 2) and ERKs (Fig. 4B,C) both showed
a biphasic dependence of activation on Ado concentration
with one phase saturating at around 10 WM and a second
phase that was activated by higher concentrations. This sug-
gests the existence of two processes. The high a⁄nity process
might be Ado receptor-mediated, whereas the low a⁄nity
process might result from deamination of Ado to hypoxan-
thine and oxidation of hypoxanthine by xanthine oxidase to
produce reactive oxygen species, which are known activators
of cardiac MAPKs [9,14,16,17].
Our results may have relevance to cardiac ischaemic pre-
conditioning [2] for which two phases have been character-
ised: an early phase that lasts only 1^3 h before the heart is
again fully susceptible to ischaemic damage, and a late phase
that appears after about 24 h and is thought be caused by
changes in gene and protein expression [3,4]. In addition to
ischaemia, preconditioning can be induced in hearts or cardiac
myocytes by exogenous Ado or with other Ado receptor ago-
nists [1]. Ado may be an endogenous mediator of precondi-
tioning in a number of species [1,3,4] although whether this is
true for rat is controversial [18,19]. Preconditioning can also
be induced by protein kinase C activation [20^23], reactive
oxygen species [24,25], K1-adrenergic agonists [26], endothe-
lin-1 [27] and bradykinin [28]. All of these activate MAPKs in
the heart, frequently through protein kinase C-dependent
mechanisms [9,13,14,16,17,29^32]. The current thinking is
that activation of protein kinase C and/or opening of ATP-
sensitive K channels may be involved [3]. However, our data
suggest that the involvement of MAPKs in preconditioning is
worthy of further investigation.
Acknowledgements: This work was supported by a Medical Research
Council Clinical Research Fellowship to S.E.A.H. and by the British
Heart Foundation.
References
[1] Downey, J.M., Liu, G.S. and Thornton, J.D. (1993) Cardiovasc.
Res. 27, 3^8.
[2] Murry, C.E., Jennings, R.B. and Reimer, K.A. (1986) Circulation
74, 1124^1136.
[3] Schwartz, E.R., Whyte, W.S. and Kloner, R.A. (1997) Curr.
Opin. Cardiol. 12, 475^481.
[4] Sumeray, M.S. and Yellon, D.M. (1997) Eur. Heart J. 18, (Suppl.
A) A8^A14.
[5] Knight, R.J. and Buxton, D.B. (1996) Biochem. Biophys. Res.
Commun. 218, 83^88.
[6] Bogoyevitch, M.A., Gillespie-Brown, J., Ketterman, A.J., Fuller,
S.J., Ben-Levy, R., Ashworth, A., Marshall, C.J. and Sugden,
P.H. (1996) Circ. Res. 79, 162^173.
[7] Yin, T., Sandhu, G., Wolfgang, C.D., Burrier, A., Webb, R.L.,
Rigel, D.F., Hai, T. and Whelan, J. (1997) J. Biol. Chem. 272,
19943^19950.
[8] Weinbrenner, C., Liu, G.-S., Cohen, M.V. and Downey, J.M.
(1997) J. Mol. Cell. Cardiol. 29, 2383^2391.
[9] Clerk, A., Fuller, S.J., Michael, A. and Sugden, P.H. (1998)
J. Biol. Chem. 273, 7228^7234.
[10] Gornall, A.G., Bardawill, C.J. and David, M.M. (1949) J. Biol.
Chem. 177, 751^766.
[11] Clerk, A. and Sugden, P.H. (1997) Biochem. J. 325, 801^810.
[12] Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llama-
zares, A., Zamanillo, D., Hunt, T. and Nebreda, A.R. (1994) Cell
78, 1027^1037.
[13] Bogoyevitch, M.A., Glennon, P.E., Andersson, M.B., Clerk, A.,
Lazou, A., Marshall, C.J., Parker, P.J. and Sugden, P.H. (1994)
J. Biol. Chem. 269, 1110^1119.
[14] Aikawa, R., Komuro, I., Yamazaki, T., Zou, Y., Kudoh, S.,
Tanaka, M., Shiojima, I., Hiroi, Y. and Yazaki, Y. (1997)
J. Clin. Invest. 100, 1813^1821.
[15] Laderoute, K.R. and Webster, K.A. (1997) Circ. Res. 80, 336^
344.
[16] Clerk, A., Michael, A. and Sugden, P.H. (1998) Biochem. J. 333,
581^589.
[17] Sabri, A., Byron, K.L., Samarel, A.M., Bell, J. and Lucchesi,
P.A. (1998) Circ. Res. 82, 1053^1062.
[18] Cave, A.C., Collis, C.S., Downey, J.M. and Hearse, D.J. (1993)
Cardiovasc. Res. 27, 663^668.
[19] Li, Y. and Kloner, R.A. (1993) Circulation 87, 1642^1648.
[20] Strasser, R.H., Braun-Dullaeus, R., Walendzik, H. and Marque-
tant, R. (1992) Circ. Res. 70, 1304^1312.
FEBS 20762 3-9-98
Fig. 4. Phosphorylation of ERKs in hearts perfused with Ado.
A: Hearts were perfused with 10 mM Ado for the times indicated
and ERK phosphorylation (p44: ERK1; p42: ERK2) was deter-
mined by immunoblotting. B: Concentration-dependent phosphory-
lation of ERKs (p44: ERK1; p42: ERK2) by Ado as determined
by immunoblotting. Hearts were perfused for 5 min with Ado. To
assist with comparison, the separate gels contained samples at over-
lapping Ado concentrations. Samples from hearts perfused with
PMA (1 WM, 5 min) were included for comparative purposes. The
right hand panel of B also shows a marker sample prepared from
neonatal rat cardiac myocytes in primary culture exposed to 1 WM
PMA for 5 min. C: Quanti¢cation of ERK1 (F, solid line) and
ERK2 (b, dashed line) phosphorylation. Results were expressed rel-
ative to the signal in PMA-perfused hearts. The experiment was re-
peated with similar results.
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